Clinical Trials Logo

Filter by:
NCT ID: NCT01320189 Completed - Obesity Clinical Trials

Dietary Protein Requirements on Unbalanced Diets

Start date: May 2011
Phase: N/A
Study type: Interventional

The objective of this study is to determine ad libitum daily energy and protein intake, energy balance and appetite profile in response to protein/carbohydrate and fat ratio over 12 consecutive days, also as a function of age, gender, BMI and FTO polymorphisms.

NCT ID: NCT01320085 Completed - Clinical trials for BRAF or NRAS Mutant Metastatic Melanoma

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Start date: March 24, 2011
Phase: Phase 2
Study type: Interventional

The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.

NCT ID: NCT01319747 Terminated - Atrial Fibrillation Clinical Trials

Video-Assisted Thoracoscopic Pulmonary Vein Isolation Versus Percutaneous Catheter Ablation in Atrial Fibrillation Trial

VATCAT
Start date: September 2010
Phase: N/A
Study type: Interventional

Recent studies demonstrated that radiofrequency isolation of the pulmonary veins (PVI) and surgically video assisted thorascopic pulmonary vein isolation (VATS-PVI) are acceptable or even superior alternatives to antiarrhythmic drug therapy in patients with symptomatically paroxysmal atrial fibrillation (AF). However, data comparing effectiveness in both interventions are limited. The investigators want to compare the effectiveness of PVI and VATS-PVI. Secondary objectives are to compare the duration of hospitalization, quality of Life, cost and to compare the satisfaction of the patients.

NCT ID: NCT01319188 Terminated - Clinical trials for Coronary Artery Disease

Ranibizumab and the Risk of Arterial Thromboembolic Events

RATE
Start date: June 2010
Phase: Phase 4
Study type: Interventional

The investigators assume that ranibizumab might be dangerous in patients with history of coronary artery disease or cerebrovascular events. The main objective of study is to reveal contraindications for ranibizumab prescription in patients with history of coronary artery disease and cerebrovascular events. Moreover, an association between management with ranibizumab and ATE rate in healthy above 50 years old persons is a concern of great interest as well.

NCT ID: NCT01319019 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Start date: December 2010
Phase: Phase 2
Study type: Interventional

This study is primarily designed to assess the dose response, dose interval, efficacy and safety of three once daily (QD) doses (100mcg, 400mcg and 800mcg) and three twice daily (BID) doses (100mcg, 200mcg and 400mcg,) of GSK961081 administered via DISKUS™ for 28 days in subjects with moderate/severe COPD versus placebo. Salmeterol 50mcg BID is included in the study as an active comparator.

NCT ID: NCT01318941 Completed - Clinical trials for Diabetic Macular Edema

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting

LUMINOUS
Start date: March 2011
Phase: N/A
Study type: Observational

This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.

NCT ID: NCT01318785 Recruiting - Lymphedema Clinical Trials

Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications

BF09-PH-01
Start date: September 2011
Phase: Phase 2
Study type: Interventional

Examination of therapeutical effects of different types of armsleeves in treating lymphatic diseases after breast cancer surgery during maintenance phase 1. thesis: - all types should be equal regarding volume reduction 2. thesis: armsleeves manufactured with microfibre yarn are expected to be - better in wearing comfort and - better in handling features.

NCT ID: NCT01318681 Completed - Clinical trials for Seasonal Allergic Rhinitis

Rhinitis, Cognition and Driving Performance

Start date: January 2011
Phase: N/A
Study type: Interventional

This study investigates the effects of Allergic Rhinitis (AR) on driving ability and memory functions. Our group has previously shown that patients suffering from AR symptoms perform less well on tasks requiring sustained attention compared to non symptomatic controls. Car driving is a typical behavior that is susceptible for changes in sustained attention and might therefore become worse under conditions when patients suffer from AR symptoms. We will compare the driving performance of untreated, symptomatic AR patients with the performance of symptomatic patients that have been treated with either a systemic AR medication (a pill) or a topical medication (nasal spray)

NCT ID: NCT01318668 Completed - Smoking Clinical Trials

A Fmri Study on the Effects of a Conjugate Vaccine and Placebo on CNS Activation and Behavior Following a Nicotine Challenge

EPU057
Start date: February 2011
Phase: Phase 1/Phase 2
Study type: Interventional

In this study the effects of a nicotine challenge on brain activity, behavior and mood will be evaluated in two groups of healthy volunteers who have a smoking habbit: The first group will undergo a series of treatments with NicVax, aimed at producing nicotine antibodies in the body and preventing nicotine to enter the brain. The second group will receive a placebo treatment. This pre-treatment (vaccination) will take place over a 18-week period. All participants will then undergo two days of testing. On each day the subjects will perform a number of psychomotor and memory tests after a challenge with nicotine (gum) or placebo(gum). Also brain activity will be studied in an fMRI scanner. We expect to see an effect on brain activation and performance only in the placebo-vaccinated group. The Nicvax vaccinated group should show activation and performance comparable to that after challenge with placebo(gum) as in this group nicotine should not cross the blood brain barrier and enter the brain

NCT ID: NCT01318486 Completed - Clinical trials for Chronic Kidney Disease

HepZero:Heparin Free Dialysis With Evodial

Start date: March 2011
Phase: N/A
Study type: Interventional

The study hypothesis is that with Evodial in patients requiring heparin free dialysis, the heparin free treatment can be performed easily (without saline flushes or blood predilution) and is at least not inferior and maybe superior to the standard care heparin free treatment in terms of clotting.